Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel
NASDAQ:CELC

Celcuity Q3 2026 Earnings Date & Estimates

Celcuity logo
$59.90 -3.29 (-5.21%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$60.00 +0.10 (+0.17%)
As of 07:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celcuity is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Celcuity in Q3 2026

Celcuity is expected to post earnings of -$1.45 per share on revenue of $2.40 million. In the same quarter a year earlier Celcuity reported -$0.92 per share. Celcuity last reported on August 13, 2026, posting -$1.44 per share and missing the -$1.16 consensus estimate. Celcuity has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$1.45
Expected Revenue
$2.40 million
Prior-Year EPS
-$0.92

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.44 (Missed by -$0.28)
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Celcuity Q3 2026 Earnings FAQ

Celcuity (NASDAQ:CELC) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Celcuity's Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Celcuity to post earnings of -$1.45 per share for Q3 2026.

The consensus revenue estimate for Celcuity is $2.40 million for Q3 2026.

Celcuity Earnings Headlines

Celcuity (CELC) Is Down 17.3% After REVTORPYK US Launch And sNDA Filing News Event
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/celcuity-celc-down-17-3-011450044.html
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
October 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/05/3374475/0/en/celcuity-announces-multiple-presentations-at-the-european-society-for-medical-oncology-esmo-congress-2026.html
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
October 15 at 1:00 AM  |  Investors Alley (Ad)
Celcuity (CELC) Dropped, So What Is Behind Its Latest Move?
October 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/celcuity-celc-dropped-behind-latest-011002119.html
Celcuity Inc. Announces Appointment of David W. Gryska to Board of Directors and Member of the Audit Committee and Compensation Committee, Effective October 1, 2026
October 2, 2026  |  marketscreener.comM
Celcuity (CELC) Gets a Buy from H.C. Wainwright
October 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CELC/pressreleases/4930349/celcuity-celc-gets-a-buy-from-hc-wainwright/
See More Celcuity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celcuity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celcuity and other key companies, straight to your email.

About Celcuity

Celcuity (NASDAQ:CELC) is a clinical-stage biotechnology company that develops functional diagnostic tests designed to help identify patients who may benefit from targeted cancer therapies. The company’s technology is intended to measure the activity of cellular signaling networks in living tumor cells, rather than relying solely on the presence or absence of individual biomarkers.

Celcuity’s proprietary CELsignia platform analyzes patient tumor samples to identify abnormal signaling activity associated with cancer growth and treatment response. The company is developing CELsignia diagnostic tests for use in oncology, including applications involving breast cancer and signaling pathways such as HER2 and PI3K. These tests are intended to support more personalized treatment decisions and may help identify patients whose tumors could respond to targeted therapies.

Based in Minneapolis, Minnesota, Celcuity works with biopharmaceutical companies and clinical research organizations to evaluate its platform and potential diagnostic applications. The company was founded by Brian Sullivan, who serves as its chief executive officer. Its products and services remain focused primarily on research, clinical development and the advancement of precision oncology diagnostics.

View Celcuity Profile
Earnings Tools